Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
In 2009, a novel H1N1 influenza A virus emerged and spread worldwide, initiating a pandemic. Various isolates obtained from disparate parts of the world were shown to be uniformly resistant to the adamantanes but sensitive to the neuraminidase inhibitors oseltamivir and zanamivir. Over time, resistance to oseltamivir became more prevalent among pandemic H1N1 virus isolates, while most remained susceptible to zanamivir. The government has proposed the use of intravenous (i.v.) zanamivir to treat serious influenza virus infections among hospitalized patients. To use zanamivir effectively for patients with severe influenza, it is necessary to know the optimal dose and schedule of administration of zanamivir that will inhibit the replication of oseltamivir-sensitive and -resistant influenza viruses. Therefore, we performed studies using the in vitro hollow-fiber infection model system to predict optimal dosing regimens for zanamivir against an oseltamivir-sensitive and an oseltamivir-resistant virus. Our results demonstrated that zanamivir, at a dose of 600 mg given twice a day (Q12h), inhibited the replication of oseltamivir-sensitive and oseltamivir-resistant influenza viruses throughout the course of the experiment. Thus, our findings suggest that intravenous zanamivir, at a dose of 600 mg Q12h, could be used to treat hospitalized patients suffering from serious infections with oseltamivir-sensitive or -resistant influenza viruses.
Virology Therapeutics and Pharmacodynamics Laboratory, Center for Biodefense and Emerging Infections, Ordway Research Institute, Center for Medical Sciences, 150 New Scotland Avenue, Albany, New York 12208, USA.
Ashley N
AN
Brown
James J
JJ
McSharry
Qingmei
Q
Weng
Jonathan R
JR
Adams
Robert
R
Kulawy
George L
GL
Drusano
D000146:Acids, Carbocyclic; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D003517:Cyclopentanes / Q000494:pharmacology; D004285:Dogs; D024882:Drug Resistance, Viral; D006146:Guanidines / Q000494:pharmacology; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects*; D053139:Oseltamivir / Q000494:pharmacology*; D053243:Zanamivir / Q000494:pharmacology*
D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; D053139:Oseltamivir; D053243:Zanamivir; C414210:peramivir
J Virol. 2009 Oct;83(20):10366-73
19641000
Antimicrob Agents Chemother. 2009 Oct;53(10):4115-26
19620324
Antimicrob Agents Chemother. 1999 Jul;43(7):1616-20
10390212
J Clin Microbiol. 2010 Nov;48(11):4228-34
20861338
Antiviral Res. 2010 Oct;88(1):38-44
20633577
Curr Opin Pediatr. 2010 Feb;22(1):83-7
20068413
JAMA. 2009 Mar 11;301(10):1034-41
19255110
J Clin Virol. 2010 May;48(1):62-5
20335065
JAMA. 2009 Mar 11;301(10):1042-6
19255111
Antimicrob Agents Chemother. 2010 Aug;54(8):3442-50
20498316
N Engl J Med. 2009 Aug 13;361(7):674-9
19564633
PLoS One. 2010 Feb 22;5(2):e9332
20179772
Emerg Infect Dis. 2006 Jan;12(1):9-14
16494710
Antimicrob Agents Chemother. 2005 Mar;49(3):981-6
15728892
N Engl J Med. 2000 Nov 2;343(18):1282-9
11058672
Emerg Infect Dis. 2010 Aug;16(8):1259-64
20678320
PLoS Curr. 2010 Mar 20;2:RRN1153
20352125
Antimicrob Agents Chemother. 2010 Jun;54(6):2575-82
20368393
N Engl J Med. 2009 Jun 18;360(25):2605-15
19423869
J Virol. 2010 Sep;84(18):9369-76
20610728
J Infect Dis. 2010 Apr 1;201(7):1007-15
20170378
Antimicrob Agents Chemother. 2006 Apr;50(4):1470-9
16569867
Nature. 2009 Aug 20;460(7258):1021-5
19672242
J Infect Dis. 2010 May 1;201(9):1397-403
20350163
N Engl J Med. 2009 Aug 13;361(7):680-9
19564631
Antimicrob Agents Chemother. 2010 Mar;54(3):1256-64
20047917
Science. 2009 Jun 19;324(5934):1557-61
19433588
Clin Infect Dis. 2010 Jun 1;50(11):1493-6
20415572
Antimicrob Agents Chemother. 2010 Jun;54(6):2517-24
20350949
Clin Infect Dis. 2010 Mar 15;50(6):860-8
20166819
Clin Infect Dis. 2010 May 1;50(9):1249-51
20367227
Antimicrob Agents Chemother. 2010 Mar;54(3):1102-10
20028826
Science. 2009 Jul 10;325(5937):197-201
19465683
Antimicrob Agents Chemother. 2011 Apr;55(4):1747-53
21263045
N Engl J Med. 2010 Jan 7;362(1):27-35
20032319
N Engl J Med. 2009 Dec 3;361(23):2204-7
19884645
JAMA. 2009 Nov 4;302(17):1872-9
19822627
N Engl J Med. 2010 Jan 7;362(1):88-9
20032317
N Engl J Med. 2009 Nov 12;361(20):1935-44
19815859
J Virol. 2002 Jun;76(11):5380-6
11991966
J Clin Virol. 2010 May;48(1):36-9
20226730
N Engl J Med. 2005 Dec 22;353(25):2633-6
16371626
MMWR Morb Mortal Wkly Rep. 2009 Apr 17;58(14):369-74
19373198
Antimicrob Agents Chemother. 2001 Mar;45(3):743-8
11181354
JAMA. 2009 Nov 4;302(17):1880-7
19822626
Clin Infect Dis. 2010 May 1;50(9):1252-5
20345239
Antimicrob Agents Chemother. 2002 Apr;46(4):1014-21
11897583
N Engl J Med. 2010 May 6;362(18):1708-19
20445182
Curr Opin Infect Dis. 2010 Apr;23(2):139-44
20087179
Clin Infect Dis. 2009 Feb 15;48(4):389-96
19133796
Antimicrob Agents Chemother. 2009 Jun;53(6):2375-81
19364864
N Engl J Med. 2010 Jan 7;362(1):45-55
20032320